Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 30 clinical trials
A Study to Assess the Reversal of the Anticoagulant Effects of JNJ-70033093 by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants

(rFVIIa) in healthy participants as measured by changes from baseline of the coagulation testing parameters (activated partial thromboplastin time [aPTT] and thrombin generation assay [TGA]).

  • 0 views
  • 05 Jun, 2021
  • 1 location
The Effect of a Levonorgestrel-releasing Intrauterine Device (IUD) Versus a Copper Containing IUD on Risk of Blood Clots

), factor VIIIc, activated partial thromboplastin time (aPTT) and activated partial thromboplastin time plus activated protein C (aPTT + APC). Both groups will undergo a GYN exam with screening

protein c
copper
levonorgestrel
d-dimer
thrombosis
  • 131 views
  • 07 Nov, 2020
  • 1 location
Valproic Acid and Dihydroergotamine as Abortive Therapy in Pediatric Migraine

The objective of this study is to compare clinical efficacy and tolerability of valproic acid (VPA) therapy versus dihydroergotamine (DHE) as abortive therapy in pediatric migraine.

  • 0 views
  • 24 Jan, 2021
  • 1 location
Early Versus Late Post Caesarean Section Oral Anticoagulation Initiation and Risk of Maternal Complications in Patients With Mechanical Heart Valve Prosthesis

A randomized cohort study applied to patients with mechanical heart valve prosthesis who will be delivered by caesarean section at or after 28 weeks of gestation . Using a table of random numbers, participants will be divided into 2 equal groups. Group A (57 patients) in which warfarin will be …

  • 0 views
  • 29 Apr, 2021
  • 1 location
Heparin Anticoagulation in Septic Shock

This study is a pragmatic open-label international randomized trial comparing therapeutic dose intravenous unfractionated heparin (UFH) to standard care venous thromboprophylaxis in patients diagnosed with septic shock.

midodrine
norepinephrine
urine output
acute renal failure
renal injury
  • 121 views
  • 04 Feb, 2021
  • 50 locations
Mesoglycan (Prisma ) Versus Placebo in Secondary Prevention of the Superficial Venous Thrombosis

The objective of the study is to demonstrate the superiority of the mesoglycan (Prisma), compared to placebo, in reducing the incidence of thromboembolic complications (relapse / extension of superficial venous thrombosis (SVT), deep venous thrombosis (DVT), pulmonary embolism (PE)) in patients who have completed the cycle of therapy of the …

  • 9 views
  • 25 Mar, 2021
  • 1 location
Efficacy And Safety Of Unfractionated Heparin In Patients With Cardiovascular Surgery Using Cardiopulmonary Bypass

surgery, based on measurements of markers of coagulation ACT, aPTT, anti-Xa heparin levels and the excessive blood loss (hemorrhage) after the end of surgery.

  • 30 views
  • 08 Nov, 2020
  • 1 location
Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A

evaluate the safety and tolerability of BIVV001 treatment. To assess the PK of BIVV001 based on the one stage activated partial thromboplastin time (aPTT) and two-stage chromogenic FVIII activity

  • 0 views
  • 03 May, 2021
  • 4 locations
A Phase 3 Open-label Interventional Study of an Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein Efanesoctocog Alfa (BIVV001) in Patients With Severe Hemophilia A

the 1-stage activated partial thromboplastin time (aPTT) and 2-stage chromogenic FVIII activity assays

severe haemophilia a
coagulation factor
treatment regimen
von willebrand factor
cryoprecipitate
  • 13 views
  • 27 Feb, 2021
  • 3 locations
Low Dose Catheter Directed Thrombolysis for Acute Pulmonary Embolism

(APTT) is 2-2.5 of reference value) or CDT (4mg alteplase (r-tPA) per catheter, infusion over 2 hours) in an open label, outcome assessor blinded, randomized, controlled trial. Primary efficacy endpoint

heparin
angiography
alteplase
acute pulmonary embolism
blood clot
  • 1 views
  • 06 May, 2021
  • 1 location